Wei Qi-Yao, Xu Yan-Ming, Lau Andy T Y
Laboratory of Cancer Biology and Epigenetics, Department of Cell Biology and Genetics, Shantou University Medical College, Shantou 515041, Guangdong, China.
Cancers (Basel). 2020 Sep 28;12(10):2783. doi: 10.3390/cancers12102783.
Conventional chemotherapy is still an important option of cancer treatment, but it has poor cell selectivity, severe side effects, and drug resistance. Utilizing nanoparticles (NPs) to improve the therapeutic effect of chemotherapeutic drugs has been highlighted in recent years. Nanotechnology dramatically changed the face of oncology by high loading capacity, less toxicity, targeted delivery of drugs, increased uptake to target sites, and optimized pharmacokinetic patterns of traditional drugs. At present, research is being envisaged in the field of novel nano-pharmaceutical design, such as liposome, polymer NPs, bio-NPs, and inorganic NPs, so as to make chemotherapy effective and long-lasting. Till now, a number of studies have been conducted using a wide range of nanocarriers for the treatment of solid tumors including lung, breast, pancreas, brain, and liver. To provide a reference for the further application of chemodrug-loaded nanoformulations, this review gives an overview of the recent development of nanocarriers, and the updated status of their use in the treatment of several solid tumors.
传统化疗仍然是癌症治疗的重要选择,但它具有细胞选择性差、副作用严重和耐药性等问题。近年来,利用纳米颗粒(NPs)提高化疗药物的治疗效果受到了关注。纳米技术通过高负载能力、低毒性、药物靶向递送、增加对靶位点的摄取以及优化传统药物的药代动力学模式,极大地改变了肿瘤学的面貌。目前,正在设想新型纳米药物设计领域的研究,如脂质体、聚合物纳米颗粒、生物纳米颗粒和无机纳米颗粒,以使化疗有效且持久。到目前为止,已经进行了许多使用各种纳米载体治疗实体瘤的研究,包括肺癌、乳腺癌、胰腺癌、脑癌和肝癌。为给载化疗药物纳米制剂的进一步应用提供参考,本综述概述了纳米载体的最新进展及其在几种实体瘤治疗中的应用现状。